These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 15929079)

  • 21. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
    Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
    Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-myc gene polymorphism and risk of thyroid cancer.
    Yaylim-Eraltan I; Bozkurt N; Ergen A; Zeybek U; Ozturk O; Arikan S; Erbil Y; Uslu I; Camlica H; Isbir T
    Exp Oncol; 2008 Jun; 30(2):117-20. PubMed ID: 18566574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer susceptibility variants alter risks in familial disease.
    Latif A; Hadfield KD; Roberts SA; Shenton A; Lalloo F; Black GC; Howell A; Evans DG; Newman WG
    J Med Genet; 2010 Feb; 47(2):126-31. PubMed ID: 19617217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphic variations in exon 10 of the luteinizing hormone receptor: functional consequences and associations with breast cancer.
    Piersma D; Verhoef-Post M; Look MP; Uitterlinden AG; Pols HA; Berns EM; Themmen AP
    Mol Cell Endocrinol; 2007 Sep; 276(1-2):63-70. PubMed ID: 17709176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding.
    McEwan IJ; Dahlman-Wright K; Ford J; Wright AP
    Biochemistry; 1996 Jul; 35(29):9584-93. PubMed ID: 8755740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
    Shen J; Ambrosone CB; DiCioccio RA; Odunsi K; Lele SB; Zhao H
    Carcinogenesis; 2008 Oct; 29(10):1963-6. PubMed ID: 18660546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years.
    Spurdle AB; Hopper JL; Chen X; Dite GS; Cui J; McCredie MR; Giles GG; Ellis-Steinborner S; Venter DJ; Newman B; Southey MC; Chenevix-Trench G
    Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):413-6. PubMed ID: 11927503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A role for common genomic variants in the assessment of familial breast cancer.
    Sawyer S; Mitchell G; McKinley J; Chenevix-Trench G; Beesley J; Chen XQ; Bowtell D; Trainer AH; Harris M; Lindeman GJ; James PA
    J Clin Oncol; 2012 Dec; 30(35):4330-6. PubMed ID: 23109704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare MYC-N11S germline mutation indicative of inherited breast cancer in a multigeneration family.
    Budurlean L; Baker M; Broach J
    BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36368728
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Liu J; Hua RX; Fu W; Zhu J; Jia W; Zhang J; Zhou H; Cheng J; Xia H; Liu G; He J
    Ann Transl Med; 2019 Sep; 7(18):475. PubMed ID: 31700911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
    Xu-Monette ZY; Deng Q; Manyam GC; Tzankov A; Li L; Xia Y; Wang XX; Zou D; Visco C; Dybkær K; Li J; Zhang L; Liang H; Montes-Moreno S; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Wang SA; Miranda RN; Piris MA; Winter JN; Medeiros LJ; Li Y; Young KH
    Clin Cancer Res; 2016 Jul; 22(14):3593-605. PubMed ID: 26927665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 8q24 allelic imbalance and MYC gene copy number in primary prostate cancer.
    Chen H; Liu W; Roberts W; Hooker S; Fedor H; DeMarzo A; Isaacs W; Kittles RA
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):238-43. PubMed ID: 20634801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis.
    Figueiredo JC; Knight JA; Cho S; Savas S; Onay UV; Briollais L; Goodwin PJ; McLaughlin JR; Andrulis IL; Ozcelik H
    BMC Cancer; 2007 Jun; 7():99. PubMed ID: 17567920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. c-MYC Asn11Ser is associated with increased risk for familial breast cancer.
    Wirtenberger M; Hemminki K; Försti A; Klaes R; Schmutzler RK; Grzybowska E; Bermejo JL; Wappenschmidt B; Bugert P; Butkiewicz D; Pamula J; Pekala W; Zientek H; Bartram CR; Burwinkel B
    Int J Cancer; 2005 Nov; 117(4):638-42. PubMed ID: 15929079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
    Adem C; Soderberg CL; Hafner K; Reynolds C; Slezak JM; Sinclair CS; Sellers TA; Schaid DJ; Couch F; Hartmann LC; Jenkins RB
    Genes Chromosomes Cancer; 2004 Sep; 41(1):1-11. PubMed ID: 15236312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
    Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
    Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.
    Sigurdson AJ; Hauptmann M; Chatterjee N; Alexander BH; Doody MM; Rutter JL; Struewing JP
    BMC Cancer; 2004 Mar; 4():9. PubMed ID: 15113441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.